Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type 2 diabetes. Previous versions were administered via injection.

Eli Lilly's solution was to ditch peptides and find an incredibly small molecule to mimic them, which can bind to the same "pocket" on the GLP-1 receptor that the peptides would target.

More than 65% of participants reached an A1C level below 6.5%. Orforglipron is the first small-molecule GLP-1 therapy to successfully complete a phase 3 trial. Eli Lilly plans to submit for ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

Onesource Specialty, a newly demerged pharma CDMO, is set to benefit from the $150 billion GLP-1 weight-loss drug boom with ...

Glucagon-like peptide 1 molecule. Image Credit: ALIOUI MA / Shutterstock. Research: Body image and interest in GLP-1 weight loss medications In a recent study published in the journal Body Image ...

Glucagon-like peptide 1 (GLP-1, 7-36) molecule — a potent antihyperglycemic hormone, neuropeptide, and incretin. Research letter: Hematologic Cancers Among Patients With Type 2 Diabetes ...

Are you weening yourself off a compounded version of the drug? Considering switching insurers in order to keep your ...